Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | UCART20X22 |
Trade Name | |
Synonyms | UCART-20x22|UCART 20x22 |
Drug Descriptions |
UCART20X22 consists of a preparation of allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both CD20 and CD22, which potentially leads to antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 551). |
DrugClasses | CD20 Immune Cell Therapy 11 CD22 Immune Cell Therapy 15 |
CAS Registry Number | NA |
NCIT ID | C193468 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
UCART20X22 | UCART20X22 | 0 | 1 |